Journal September 26, 2026 5 min read

Common Misconceptions About Mucosal Healing

Mucosal healing is a recognised therapeutic endpoint in ulcerative colitis, but its assessment and mechanisms are often misunderstood. This page examines the evidence on biomarkers, experimental models, and research comp

peptides-pro Editorial

What is mucosal healing?

Mucosal healing is the restoration of the intestinal epithelial barrier and resolution of endoscopic lesions in inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). It is recognised as the best therapeutic endpoint in UC, but its use in daily practice is limited by the low acceptability of repeated colonoscopies [3]. This limitation has driven interest in non-invasive biomarkers and experimental models to understand the healing process.

Research into mucosal healing centres on pathways that regulate epithelial repair and inflammation, including the NAD-dependent deacetylase sirtuin-1 (SIRT1)/signal transducer and activator of transcription 3 (STAT3) signalling axis, which has been studied in the context of ulcerative colitis [1].

Research Studies

GHK-Cu and SIRT1/STAT3 signalling in a DSS-induced murine model of colitis

Glycyl-l-histidyl-l-lysine-copper (GHK-Cu) is a copper-binding tripeptide with known anti-inflammatory properties. A study using a dextran sulfate sodium (DSS)-induced murine model of UC evaluated the therapeutic potential of GHK-Cu, with emphasis on its regulatory effects on the SIRT1/STAT3 pathway [1]. The study was designed to systematically assess mechanisms in this animal model. Findings from this preclinical work are specific to the DSS-induced murine model and do not establish effects in humans.

Lactobacillus probiotics and trace elements in ulcerative colitis patients

An interventional observational study is evaluating the efficacy and safety of lactobacillus probiotics or trace elements when added to infliximab in maintaining remission in UC patients. The study compares the efficacy of adding lactobacillus probiotics versus adding trace elements to infliximab in an open-label, parallel, prospective design conducted at the National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt. Recruited patients are randomly allocated to one of three groups; Group I receives 20 billion colony forming units [2]. This study is ongoing and results are not yet available.

Serum and fecal biomarkers for predicting mucosal healing in ulcerative colitis

Fecal calprotectin has shown very good negative predictive value to eliminate IBD diagnosis, good correlation with endoscopic activity, and good ability to predict relapse. However, its use in daily practice is limited by the low acceptability of repeated colonoscopies [3]. Recent work, including by the study team, indicates that fecal biomarkers such as Chitinase 3-Like 1 (CHI3L1) and matrix metalloprotease type 9 (MMP-9), as well as serum biomarkers neutrophil gelatinase B-complex associated lipocalin (NGAL)-MMP9 and serum CHI3L1, could be better predictors of mucosal healing [3]. These findings are from observational studies and require further validation.

Regulation of mucosal healing in inflammatory bowel disease: biopsy-based approach

A study is comparing non-healing colonic ulcers in patients with IBD to iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. Using a "biopsy of the biopsy" approach, patients are biopsied at baseline and again at a follow-up visit to reveal patterns about gene expression and mitochondrial function during ulcer healing [4]. This research is ongoing and aims to elucidate mechanisms of healing in human tissue.

Therapeutic approaches to malnutrition enteropathy in children

The TAME study is evaluating four new approaches compared against standard care for malnutrition enteropathy in children with severe acute malnutrition. A high pathogen burden causes damage to the intestinal mucosa, exacerbating nutritional impairment and leading to further susceptibility to infection and impaired epithelial regeneration. Enteropathy is characterised by multiple epithelial breaches, microbial translocation from gut lumen to systemic circulation, and systemic inflammation. The trial evaluates four interventions (colostrum, N-acetyl glucosamine, teduglutide, and budesonide) given for 14 days [5]. This study is ongoing and results are not yet available.

Zinc L-carnosine and oral mucosal healing

A systematic review and meta-analysis evaluated the protective and healing effects of zinc L-carnosine (ZnC) on the oral mucosa. ZnC is a cytoprotective compound with anti-inflammatory, antioxidant, and epithelial reparative properties. Oral mucosal injury is a frequent complication in oncologic and surgical settings, significantly affecting quality of life [6]. This evidence is from a systematic review and meta-analysis of clinical studies, but it pertains to the oral mucosa, not the intestinal mucosa, and should not be extrapolated to IBD.

Comparison of biomarkers for mucosal healing

Biomarker	Sample Type	Reported Utility
Fecal calprotectin	Feces	Very good negative predictive value to eliminate IBD diagnosis; good correlation with endoscopic activity; good ability to predict relapse [3]
CHI3L1	Feces and serum	Could be better predictor of mucosal healing [3]
MMP-9	Feces	Could be better predictor of mucosal healing [3]
NGAL-MMP9	Serum	Could be better predictor of mucosal healing [3]

Animal and in vitro evidence

Some evidence on mucosal healing comes from animal models or in vitro studies. For example, the GHK-Cu study used a DSS-induced murine model of colitis [1]. Such findings are valuable for understanding mechanisms but do not directly translate to human clinical outcomes. The zinc L-carnosine review focused on oral mucosa, which differs from intestinal mucosa [6].

If you are reading this for personal health reasons

The compounds and interventions discussed here are sold for laboratory research purposes only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.